This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This randomized clinical trial assesses whether cardioverter-defibrillator implantation is more effective than amiodarone therapy for the primary prevention of all-cause mortality and secondary prevention of sudden cardiac death, hospitalization for heart failure, and use of a pacemaker among patients with chronic Chagas cardiomyopathy.
Better risk stratification is needed to evaluate patients with non-ischemic cardiomyopathy (NICM) for prophylactic implantable cardioverter-defibrillators (ICD). Growing evidence suggests cardiac magnetic resonance imaging (CMR) may be useful in this regard.
He was defibrillated, but they also noticed that he was being internally defibrillated and then found that he had an implantable ICD. He was unidentified and there were no records available After 7 shocks, he was successfully defibrillated and brought to the ED. Bedside US shows extremely poor EF with dilated cardiomyopathy.
The goal of the CHAGASICS trial was to evaluate implantable cardioverter-defibrillators (ICDs) compared with amiodarone among patients with chronic Chagas cardiomyopathy.
Hypertrophic cardiomyopathy (HCM) is associated with risk of sudden cardiac death (SCD). Since approval in late 2012, the subcutaneous implantable cardioverter-defibrillator (SICD) has been used as an alternative to the traditional transvenous ICD (TV-ICD) for SCD prevention in HCM.
Cardiac sarcoidosis (CS), a rare condition characterized by non-caseating granulomas, can manifest with symptoms such as atrioventricular block and ventricular tachycardia (VT), as well as mimic inherited cardiomyopathies. A 58-year-old woman presented with sustained VT with a prior diagnosis of hypertrophic cardiomyopathy (HCM).
Hypertrophic cardiomyopathy (HCM) is associated with risk of sudden cardiac death (SCD). Since approval in late 2012, the subcutaneous implantable cardioverter-defibrillator (SICD) has been used as an alternative to the traditional transvenous ICD (TV-ICD) for SCD prevention in HCM.
Implantable cardioverter defibrillators (ICD) have proved their favourable outcomes on survival in selected patients with cardiomyopathy. However, recent studies have questioned the protective role of ICD in non-ischemic cardiomyopathy (NICM) for primary prevention.
AimsThis retrospective cohort study aimed to investigate the efficacy of dual-chamber left Bundle branch pacing (LBBP) as an alternative therapy for heart failure patients with complete left bundle branch block (CLBBB) and indications for defibrillator with cardiac resynchronization therapy (CRT-D).Methods34 to 61.06.0% (P<0.001).
Clinical introduction A patient in his 60s with a history of ischaemic cardiomyopathy and severely reduced left ventricular ejection fraction of 20% presents with worsening dyspnoea on exertion. mL/kg/min) despite maximal effort.
Implantable cardioverter defibrillator (ICD) prevents sudden cardiac death (SCD) in patients with ischemic cardiomyopathy (ICM). Catheter ablation has been shown to effectively reduce ventricular tachycardia (VT) recurrence, yet its efficacy in patients without an ICD implantation remains uncertain.
An 18-year-old male with arrhythmogenic cardiomyopathy was referred for catheter ablation of ventricular tachycardia after experiencing appropriate implantable cardioverter-defibrillator (ICD) shock. Six months prior, he had undergone uncomplicated implantation of an extravascular ICD (EV-ICD) [1].
Patients with hypertrophic cardiomyopathy (HCM) are at risk for sudden death and individuals with ≥1 major risk markers are considered for primary prevention implantable cardioverter defibrillators. Guidelines recommend cardiac magnetic resonance imaging (CMR) to identify high-risk imaging features.
Predictive factors of benefit from implantation of an implantable cardioverter-defibrillator (ICD) for primary prophylaxis of sudden cardiac death in patients with nonischemic cardiomyopathy (NICM) have not been clarified.
Hypertrophic cardiomyopathy (HCM) predisposes patients to cardiac arrest (CA). While established major risk factors may warrant the need for primary prevention by implantable cardioverter-defibrillator (ICD), it is unknown if specific electrocardiographic predictors increase the risk of CA.
The efficacy of implantable cardioverter-defibrillators (ICD) in patients with a non-ischaemic cardiomyopathy (NICM) is being debated. Deep Learning models enable feature extraction from high-dimensional data, such as cardiac MRI (CMR) and ECG.
He was defibrillated into VT. He then underwent dual sequential defibrillation into asystole. VF should make you think of ischemia, cardiomyopathy (especially scar from old MI), or one many other cardiac but non-ischemic etiologies. This patient was witnessed by bystanders to collapse. They started CPR. sodium bicarbonate.
The American College of Cardiology (ACC) and the American Heart Association (AHA) today released a new clinical guideline for effectively managing individuals diagnosed with hypertrophic cardiomyopathy (HCM). Ommen, MD, FACC , medical director of the Mayo Hypertrophic Cardiomyopathy Clinic and chair of the guideline writing committee.
Progressive decline across periods in mortality rates among patients with implantable cardioverter-defibrillator (ICD). Abstract Introduction Despite advancements in implantable cardioverter-defibrillator (ICD) technology, sudden cardiac death (SCD) remains a persistent public health concern.
Background Consensus guidelines support the use of implanted cardioverter-defibrillators (ICD) for primary prevention of sudden cardiac death in patients with either non-ischaemic or ischaemic cardiomyopathy with left ventricular ejection fraction (LVEF) ≤35%.
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disease characterised by fibrofatty replacement of the ventricular myocardium due to specific mutations, leading to ventricular arrhythmias and sudden cardiac death. channels, Connexin 43 and Wnt signalling, potentially modifying myocardial fibrosis.
She spontaneously converted (Defibrillation was not performed). Most such rhythms in the setting of ischemia are VF and will not convert without defibrillation. There was hyperkinesis of the basal segments and findings were interpreted as typical of takotsubo cardiomyopathy. At this time the following blood test were available.
Accurate risk stratification allows for timely implantation of intracardiac defibrillators (ICD) and is currently performed using a multimodality prediction model. (Arg14del) variant carriers are at risk of developing malignant ventricular arrhythmias (MVA).
Timely diagnosis has significant implications for clinical management, allowing for disease-modifying therapy or implantable cardioverter-defibrillator (ICD) insertion. Conduction system disturbance may represent an early manifestation of underlying structural heart disease, including infiltrative disorders such as sarcoidosis.
Two sisters, diagnosed four days apart with a serious heart condition, explain how hypertrophic cardiomyopathy (and having defibrillators implanted) has changed their lives in surprising ways.
Better stratification of risk, the researchers say, would help clinicians to identify people in need of an implantable cardioverter defibrillator (ICD) – a device that monitors heart rhythm and shocks the heart back into a normal rhythm if needed. It adds a missing part of the puzzle.”
He had a background of arrhythmic right ventricular cardiomyopathy. He had previously undergone the placement of a dual-chamber implantable cardioverter-defibrillator for atrioventricular block and ventricular tachycardia (VT). Clinical introduction A man in his 50s presented to the emergency department with palpitations.
This study explores the roles of cTnI (cardiac troponin I) and CK-MB in hypertrophic cardiomyopathy (HCM).Methods:This Routine cTnI and CK-MB assessments may help to guide implantable cardioverter defibrillator implantation for primary prevention in HCM.
In the subgroup with Class 3 of recommendation for implantable cardioverter defibrillator, patients with absolute LV-GLS ≤ 9% showed significantly worse prognosis than those with absolute LV-GLS > 9% (p =.002 Circulation, Volume 150, Issue Suppl_1 , Page A4142952-A4142952, November 12, 2024. vs -266.2; vs -264.9; 009), respectively.
It is commonly encountered in infiltrative cardiomyopathies but may be associated with myocarditis. Options include a ‘watch-and-wait’ policy, anti-arrhythmic drugs, consideration of a permanent pacemaker or, alternatively, a wearable or implantable cardioverter-defibrillator (ICD).
In patients with heart failure (HF) undergoing left bundle branch area pacing (LBBAP) for cardiac resynchronization therapy (CRT) without a defibrillator (e.g., elderly patients or non-ischemic cardiomyopathy, in whom the use of a defibrillator has been questioned),1 the use of a right ventricular (RV) lead may not be necessary.
Most patients with VT and structural heart disease preparing for ablation either have or are about to receive an implantable cardioverter defibrillator (ICD) shortly after the procedure to prevent sudden cardiac death from recurrent ventricular arrhythmias (VA).
And of course Ken's comments at the bottom) An elderly obese woman with cardiomyopathy, Left bundle branch block, and chronic hypercapnea presented hypoxic with altered mental status. I do not see OMI here and all trops were only minimally elevated, consistent with either chronic injury from cardiomyopathy or with acute injury from sepsis.
Tackling SCD was in God’s domain, until the brilliance of Dr. Michel Mirowski shrunk the defibrillator and implanted it under the chest in 1980. (Dr. 2020) The un-disputable fact is ischemic DCM has a target to treat, though it is termed as cardiomyopathy. SCD is the leading cause of mortality in heart failure. N Engl J Med.
After resuscitation and defibrillation , there were no more episodes of TdP. Below is the patient’s 12 lead ECG following defibrillation. The patient was diagnosed with stress cardiomyopathy. Widespread T wave inversions and prolongation of the QT interval is not uncommon in Takotsubo cardiomyopathy.
We describe a case of ventricular pacemaker spikes delivered on the T wave causing PMVT.Case:A 53-year-old female with CAD s/p stent, postpartum cardiomyopathy s/p Bi-V CRT-D (Boston Scientific G124), and paroxysmal atrial fibrillation presented for elective endoscopy and colonoscopy to evaluate her dysphagia and abdominal pain.
Methods CASTLE-VT is a randomized evaluation of prophylactic ablative treatment of arrhythmogenic ventricular scar in patients referred for HTx evaluation and diagnosed with ICM. The primary endpoint is the composite of all-cause mortality, worsening of HF requiring prioritized transplantation or LVAD implantation.
She was successfully revived after several rounds of ACLS including defibrillation and amiodarone. The most important clinical entity associated with motion alternans is large pericardial effusion — though motion alternans has also been observed in some cases of hypertrophic cardiomyopathy.
CardiomyopathyCardiomyopathy is a condition that affects the heart muscle, causing it to become enlarged, thick, or rigid. Excessive Alcohol or Drug Use Long-term abuse of alcohol or certain drugs can weaken the heart muscle, resulting in cardiomyopathy and eventually cardiomegaly.
Arrhythmogenic cardiomyopathy Long QT syndrome Hypertrophic cardiomyopathy. This episode self terminated before defibrillation was possible. There are a number of things to look for in an ECG that can hint at arrhythmia as the cause of an apparent seizure. I measure the RR interval at 795ms and the QT interval at 475ms.
Today's case reminds us of the intuitive logic that if a patient has a shockable arrest ( ie, VFib ) — and following successful defibrillation shows evidence of acute OMI ( even if STEMI criteria are not necessarily fulfilled ) — that such patients have much to gain from immediate cath with PCI. (
vs. 28.8%, p < 0.001), more often had ischeemic cardiomyopathy (49.8% 1.70) and implantable cardioverter-defibrillator (ICD) (multivariable HR 1.40, 95% CI 1.01–1.95). Multivariable Cox regression and propensity score matching (PSM) analyses were performed. ml/min/1.73 m ml/min/1.73 m 76.5], p < 0.001).
Ultimately the patient underwent implantation of secondary prevention implantable cardioverter-defibrillator and initiation of sotalol.Discussion:The prevalence of MAD is approximately 30% in those with MVP and 8% in the general population. Electrocardiogram (ECG) showed sustained monomorphic VT at a rate of 160 bpm.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content